Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

10.35
+0.44004.44%
Volume:2.30M
Turnover:24.17M
Market Cap:601.74M
PE:-4.20
High:11.00
Open:10.77
Low:10.21
Close:9.91
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:1.50
T/O Rate:5.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.44
PE(LYR):-4.58

Loading ...

Alliance Global Partners Keeps Their Buy Rating on Capricor Therapeutics (CAPR)

TIPRANKS
·
Mar 14

Capricor Therapeutics Inc : B. Riley Raises Target Price to $63 From $50

THOMSON REUTERS
·
Mar 13

B. Riley Adjusts Price Target on Capricor Therapeutics to $63 From $50, Maintains Buy Rating

MT Newswires Live
·
Mar 13

Capricor Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 13

Capricor Therapeutics Q4 Loss Widens

MT Newswires Live
·
Mar 13

Earnings Flash (CAPR) Capricor Therapeutics Posts Q4 Loss $-0.62, vs. FactSet Est of Loss of $-0.55

MT Newswires Live
·
Mar 13

Capricor announces additional analyses, outcomes from Phase 3 HOPE-3 trial

TIPRANKS
·
Mar 12

Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

GlobeNewswire
·
Mar 12

Roth MKM Remains a Buy on Capricor Therapeutics (CAPR)

TIPRANKS
·
Mar 11

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 11

Capricor Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview

Reuters
·
Mar 11

Sector Update: Health Care Stocks Mixed Tuesday Afternoon

MT Newswires Live
·
Mar 11

Capricor Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 10

Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review

Benzinga_recent_news
·
Mar 10

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and Capricor Therapeutics (CAPR)

TIPRANKS
·
Mar 10

BUZZ-Capricor surges as FDA resumes review of muscle‑wasting disease drug

Reuters
·
Mar 10

Capricor announces establishment of new PDUFA date for dermiocel BLA

TIPRANKS
·
Mar 10

Capricor Shares Rise 11% After FDA Resumes Review of Co's Drug for Muscle-Wasting Condition

THOMSON REUTERS
·
Mar 10

FDA sets Aug. 22, 2026 PDUFA date for Capricor’s deramiocel BLA after lifting CRL

Reuters
·
Mar 10

Capricor Therapeutics Inc - Pdufa Target Action Date for Deramiocel Set for August 22, 2026

THOMSON REUTERS
·
Mar 10